Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting market conditions” and the need to focus on bit.bio’s “core strengths,” a spokesperson said. Source: Fierce Biotech 19/3/2025